Understand the source comparison
Peptide Research News October 2026 Roundup: Research Compound Comparison
Before selecting peptides for metabolic, cognitive, or immune research protocols, understanding mechanism-specific advantages across compound classes prevents mismatched applications and wasted resources. Survodutide Dual GLP-1/glucagon receptor agonist 18.6%
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting peptides for metabolic, cognitive, or immune research protocols, understanding mechanism-specific advantages across compound classes prevents mismatched applications and wasted resources.
- Survodutide
- Dual GLP-1/glucagon receptor agonist
- 18.6% mean weight loss + 68.3% liver fat reduction at 48 weeks (SYNCHRONIZE-NASH)
- 2.4–4.8mg SC weekly
- The dual-receptor approach breaks the 15–20% weight loss ceiling single-agonist protocols consistently hit. Glucagon component drives hepatic fat oxidation independent of caloric deficit
- Thymalin
- Thymic epithelial cell activator (FOXN1/HOXA3 transcription)
- 43% increase in naïve T-cell populations in adults 65–78 after 12 weeks (Scripps/Nature Aging)
- 10mg SC twice weekly × 12 weeks
- First peptide to demonstrate quantifiable thymic reactivation in aging populations. Addresses immunosenescence at the organ level, not just downstream immune markers
- Dihexa
- HGF receptor agonist (c-Met pathway, synaptogenesis)
- 23% pattern recognition improvement sustained 6 months post-treatment in early Alzheimer's (Phase 2b)
- 0.5–2mg oral daily × 4–8 weeks
- The six-month cognitive persistence despite 40-minute half-life suggests lasting structural neuroplasticity. Not transient receptor binding like most nootropics
- Cerebrolysin
- Neurotrophic peptide mixture (BDNF, NGF analogs)
- 4.8-point MMSE improvement in post-stroke patients, sustained at 12-month follow-up (multicentre EU trial)
- 10–30mL IV daily × 10–20 days
- Porcine-derived peptide blend. Mechanism less understood than synthetic analogs but clinical track record in stroke recovery is unmatched across peptide classes